Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: Implications for hypertension

Journal of Hypertension

Volumn 28, Issue 1, 2010, Pages 111-118

  Calò, Lorenzo A ^a   Schiavo, Silvia ^a   Davis, Paul A ^b   Pagnin, Elisa ^a   Mormino, Paolo ^a   D'Angelo, Angela ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II signaling; ERK 1 2; Gitelman's syndrome; MKP 1

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; ARTICLE; BARTTER SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FIBROBLAST; GITELMAN SYNDROME; HUMAN; HUMAN CELL; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; WESTERN BLOTTING;

EID: 73849128374     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328332b738     Document Type: Article

References (42)

1. Mehta PK, Griendling KK. Angiotensin II cell signaling. Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 92:C82-C97.
2. Touyz RM. Role of angiotensin II in regulating vascular structural and functional changes inhypertension. Curr Hypertens Rep 2003; 5:155-164.
3. Ruiz Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5:73-79.
4. Dzau VJ, Lopez-Ilasaca M. Searching for transcriptional regulators of Ang II-induced vascular pathology. J Clin Invest 2005; 115:2319-2322.
5. Kim S, Iwao H. Molecular and cellular mechanisms of Ang II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52:11-34.
6. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004; 110:1456-1462. (Pubitemid 39238023)
7. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008; 21:500-508.
8. Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, Dige-Petersen H, Ibsen H. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFEsubstudy. Blood Press 2005; 14:177-183.
9. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation 2001; 103:919-925.
10. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular diseases? J Hypertens 2003; 21:1429-1443.
11. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in humans essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
12. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. TEM 2000; 11:1-6.
13. Naesens M, Steels P, Verberckmoes R, Vanrenterghem Y, Kuypers D. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol 2004; 96:65-78.
14. Calo LA. Vascular tone control in humans: the utility of studies in Bartter's/ Gitelman's syndromes. Kidney Int 2006; 69:963-966.
15. Calo LA, Pessina AC, Semplicini A. Angiotensin II signaling in the Bartter's and Gitelman's syndromes, a negative human model of hypertension. High Blood Press Cardiovasc Prev 2005; 12:17-26.
16. Calo LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens 2007; 25:259-264.
17. Calo LA, Puato M, Schiavo S, Zanardo M, Tirrito C, Pagnin E, Balbi G, et al. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrol Dial Transplant 2008; 23:2804-2809.
18. Calo LA, Montisci R, Scognamiglio R, Davis PA, Pagnin E, Schiavo S, Mormino P et al. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes). are angiotensin II type 2 receptors involved? J Endocrinol Invest 2009 E-published ahead of print 14 July 2009, DOI: 10.3275/6430.
19. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993; 75:487-493.
20. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR. The Dual Specificity mitogen-activated protein kinase phosphatase 1 and 2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997; 272:1368-1376.
21. Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999; 286:2514-2517.
22. Calo LA, Pagnin E, Ceolotto G, Davis PA, Schiavo S, Papparella I, Semplicini A, et al. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. J Hypertens 2008; 26:938-945.
23. Semplicini A, Lenzini L, Sartori M, Papparella I, Calo LA, Pagnin E, Strapazzon G, et al. Reduced expression of regulator of G protein signaling-2 in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24:1115-1124.
24. Calo LA, Pagnin E, Davis PA, Sartori M, Ceolotto G, Pessina AC, Semplicini A. Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's sydrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 2004; 89:4153-4157.
25. Hansen JL, Servant G, Baranski TJ, Fujita T, Iiri T, Sheikh SP. Functional reconstitution of the angiotensin II type 2 receptor and Gi activation. Circ Res 2000; 87:753-759.
26. Savoia C, Tabet F, Yao G, Schiffrin E, Touyz R. Negative regulation of Rho/ Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 2005; 23:1037-1045.
27. 3~ and cyclic GMP levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27:874-879.
28. Calò L, Davis PA, Milani M, Cantaro S, Antonello A, Favaro S, D'Angelo A. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51:12-17.
29. Pagnin E, Davis PA, Sartori M, Semplicini A, Pessina AC, Calò LA. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling. J Hypertens 2004; 22:1963-1969.
30. Pagnin E, Semplicini A, Sartori M, Pessina AC, Calò LA. Reduced mRNA and protein content of Rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes. Relevance for the pathophysiology of hypertension. Am J Hypertens 2005; 18:1200-1205.
31. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41:99-107.
32. Davis PA, Pagnin E, Semplicini A, Avogaro A, Calò LA. Insulin signaling, glucose metabolism and the angiotensin II signaling system. Studies in Bartter's/Gitelman's syndromes. Diabetes Care 2006; 29:469-471.
33. Calò LA, Davis PA, Palatini P, Semplicini A, Pessina AC. Urinary albumin excretion, endothelial dysfunction and cardiovascular risk: study in Bartter's/Gitelman's syndromes and relevance for hypertension. J Hum Hypertens 2007; 21:904-906.
34. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor bradykinin B2 receptor functional heterodimerization. Hypertension 2006; 48:316-322.
35. Wieland T, Lutz S, Chidiac P. Regulators of G protein signaling: a spotlight on emerging functions in the cardiovascular system. Curr Opin Pharmacol 2007; 7:1-7.
36. Le TH, Coffman TM. RGS2. a 'turn-off' in hypertension. J Clin Invest 2003; 111:441-443.
37. Steckelings UM, Kaschina E, Unger TH. The AT2 receptor: a matter of love and hate. Peptides 2005; 26:1401-1409.
38. Calò LA, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, et al. Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001; 60:882-889.
39. Calò LA, Davis PA, Semplicini A. Reduced content of alpha subunit of Gq protein in monocytes of Bartter and Gitelman syndromes: relationship with vascular hyporeactivity. Kidney Int 2002; 61:353-354.
40. Calò LA, Pagnin E, Davis PA, Sartori M, Semplicini A. Oxidative stress related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003; 18:1518-1525.
41. Calò LA, Sartore G, Bassi A, Basso C, Bertocco S, Marin R, Zambon S, et al. Reduced susceptibility of low density lipoprotein to oxidation in patients with overproduction of nitric oxide (Bartter's and Gitelman's syndrome). J Hypertens 1998; 16:1001-1008.
42. Siragy HM. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep 2008; 10:261-267.